ArticleNPJ breast cancer2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Linda T Vahdat et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this paperpooled itcites it